Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to presen...
TissueCypher® Barrett’s Esophagus test adds approximately $1 billion to Castle’s estimated U.S. TAM and drives expansion into gastrointestinal market Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease ma...
Presented at American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced oral presentation...
Data demonstrated that patients with a DecisionDx-Melanoma Class 1A (low risk) test result had a five-year recurrence-free survival rate and distant metastasis-free survival rate of 95.8% and 99.2%, respectively Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying inn...
Inaugural roundup of companies includes top 250 that proved management excellence across the middle market Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that it...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that the Company has been named a 2021 Houston Chronicle Top Workplace. Of the 2,768 companies in the Houston area who par...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to...
Castle Biosciences, Inc. (CSTL) Q3 2021 Earnings Conference Call November 08, 2021, 04:30 PM ET Company Participants Camilla Zuckero - Executive Director, IR & Corporate Communications Derek Maetzold - Founder, President & CEO Frank Stokes - CFO Conference Call Participants Sung Ji Na...
Castle Biosciences (NASDAQ:CSTL): Q3 GAAP EPS of -$0.47 misses by $0.06. Revenue of $23.5M (+54.6% Y/Y) beats by $0.53M. Press Release For further details see: Castle Biosciences EPS misses by $0.06, beats on revenue
Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...